Yüklüyor......
Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
Brentuximab vedotin (BV) is an effective and well-tolerated treatment for patients with classical Hodgkin lymphoma (HL). It was initially approved by the US FDA for the treatment of HL after failure of autologous hematopoietic stem cell transplant (autoHSCT) or after failure of at least two prior li...
Kaydedildi:
| Yayımlandı: | Ther Adv Hematol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6130098/ https://ncbi.nlm.nih.gov/pubmed/30210755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620718786833 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|